BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31387567)

  • 21. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR
    Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological, Radiological, and Molecular Features of Primary Lung Adenocarcinoma with Morule-Like Components.
    Wang LL; Ding L; Zhao P; Guan JJ; Ji XB; Zhou XL; Shao SH; Zou YW; Fu WW; Lin DL
    Dis Markers; 2021; 2021():9186056. PubMed ID: 34234879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions.
    Liu Q; Huang Q; Yu Z; Wu H
    Clin Respir J; 2022 Mar; 16(3):216-225. PubMed ID: 35081265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.
    Kuang X; Xiao J; Dai LX; Zhang LH; He BX
    Transl Cancer Res; 2019 Jun; 8(3):736-751. PubMed ID: 35116812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
    Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
    Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
    Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens.
    Ma Y; Du Y; Wang R; Ji X; Wu J; Liu Y; Guo X; Zhang Y
    Pathol Res Pract; 2020 Aug; 216(8):153036. PubMed ID: 32703499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
    Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
    Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data.
    Zhao S; Cong X; Liu Z
    Biomed Res Int; 2021; 2021():8817898. PubMed ID: 33997043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene.
    Kometani T; Sugio K; Osoegawa A; Seto T; Ichinose Y
    Thorac Cancer; 2018 May; 9(5):563-570. PubMed ID: 29517858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and Validation of a Novel Signature to Predict Overall Survival in "Driver Gene-negative" Lung Adenocarcinoma (LUAD): Results of a Multicenter Study.
    Cui Y; Fang W; Li C; Tang K; Zhang J; Lei Y; He W; Peng S; Kuang M; Zhang H; Chen L; Xu D; Tang C; Zhang W; Zhu Y; Jiang W; Jiang N; Sun Y; Chen Y; Wang H; Lai Y; Li S; He Q; Zhou J; Zhang Y; Lin M; Chen H; Zhou C; Wang C; Wang J; Zou X; Wang L; Ke Z
    Clin Cancer Res; 2019 Mar; 25(5):1546-1556. PubMed ID: 30389658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
    Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
    Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Driver gene alterations in lung adenocarcinoma: Demographic features of 2544 Chinese cases.
    Hu M; Zhang T; Yang Y; Che N; Li J; Liu Z; Li B
    Int J Biol Markers; 2020 Dec; 35(4):44-50. PubMed ID: 33063618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characteristics of genomic alterations of lung adenocarcinoma in young never-smokers.
    Luo W; Tian P; Wang Y; Xu H; Chen L; Tang C; Shu Y; Zhang S; Wang Z; Zhang J; Zhang L; Jiang L; Liu L; Che G; Guo C; Zhang H; Wang J; Li W
    Int J Cancer; 2018 Oct; 143(7):1696-1705. PubMed ID: 29667179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach.
    Yoon HJ; Sohn I; Cho JH; Lee HY; Kim JH; Choi YL; Kim H; Lee G; Lee KS; Kim J
    Medicine (Baltimore); 2015 Oct; 94(41):e1753. PubMed ID: 26469915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
    Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
    Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.
    Zhao Y; Pan Y; Cheng C; Zheng D; Zhang Y; Gao Z; Fu F; Li H; Zheng S; Zhuge L; Mao H; Kuang M; Tao X; Peng Y; Hu H; Xiang J; Li Y; Sun Y; Chen H
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1781-1789. PubMed ID: 32361787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.